A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome

J Pritchard; IA Grau; ZR Idrissova; BR Lecky; Ian Sutton; AW Swan; HJ Willison; John Winer; RA Hughes

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome

J Pritchard, IA Grau, ZR Idrissova, BR Lecky, Ian Sutton, AW Swan, HJ Willison, John Winer, RA Hughes

Birmingham Medical School

Research output: Contribution to journal › Article

52 Citations (Scopus)

Abstract

The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.

Original language	English
Pages (from-to)	1282-4
Number of pages	3
Journal	Neurology
Volume	61
Issue number	9
Publication status	Published - 1 Jan 2003

Cite this

@article{a472c1f5849e4f79b7bb12ce1fd81439,

title = "A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome",

abstract = "The authors recruited 19 nonambulant patients with Guillain-Barr{\'e} syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.",

author = "J Pritchard and IA Grau and ZR Idrissova and BR Lecky and Ian Sutton and AW Swan and HJ Willison and John Winer and RA Hughes",

year = "2003",

month = jan,

day = "1",

language = "English",

volume = "61",

pages = "1282--4",

journal = "Neurology",

issn = "0028-3878",

publisher = "American Academy of Neurology",

number = "9",

}

TY - JOUR

T1 - A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome

AU - Pritchard, J

AU - Grau, IA

AU - Idrissova, ZR

AU - Lecky, BR

AU - Sutton, Ian

AU - Swan, AW

AU - Willison, HJ

AU - Winer, John

AU - Hughes, RA

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.

AB - The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.

M3 - Article

C2 - 14610140

SN - 0028-3878

VL - 61

SP - 1282

EP - 1284

JO - Neurology

JF - Neurology

IS - 9

ER -

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome

Abstract

Fingerprint

Cite this